NCT00679367View on ClinicalTrials.gov

Melphalan, Lenalidomide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis

PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

May 31, 2008

Primary Completion Date

May 31, 2015

Study Completion Date

May 31, 2015

Conditions
Multiple Myeloma
Interventions
DRUG

dexamethasone

40 mg once weekly

DRUG

lenalidomide

10 mg/day D1-21

DRUG

melphalan

5 mg/m2 D1-4

Trial Locations (1)

02118

Boston University Cancer Research Center, Boston

Sponsors
All Listed Sponsors
lead

Boston Medical Center

OTHER

NCT00679367 - Melphalan, Lenalidomide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis | Biotech Hunter | Biotech Hunter